Author: MoonLake Immunotherapeutics AG

MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update

November 4, 2026
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

August 10, 2026

MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update